Tick box questionnaire could significantly improve oesophageal cancer survival rates

6th December 2019

Guts UK funded researchers at University College London have discovered that a simple health questionnaire could be a highly effective tool to pre-screen people for early signs of oesophageal cancer, enabling much earlier diagnosis and treatment.

The research used artificial intelligence to analyse a large oesophageal cancer dataset  of 1,299 patients to establish which health factors were common in those individuals who had Barrett’s oesophagus.

Barrett’s oesophagus is a condition where the cells of the oesophagus (gullet) grow abnormally and is usually caused by acid reflux. Barret’s oesophagus is not a cancer, but is the only known pre-cursor for oesophageal cancer, increasing the risk of cancer by 30 to 60 fold.

Each year, around 9,100 people in the UK are diagnosed with oesophageal cancer and the long term survival rate for patients is only 12%, but 59% of cases are preventable. However there is currently no national screening programme, unlike breast, bowel and cervical cancer.

Significantly, AI found eight factors: age; gender; smoking; waist circumference; frequency of stomach pain; duration of heartburn; acid taste; and taking of acid suppression medicines, which were markers in those individuals who either had Barrett’s oesophagus or went onto develop it.

The risk factors identified by AI were then tested on a different oesophageal cancer dataset of 398 patients, and the conclusions were the same.

“Our evidence highlights a set of risk factors, which could act as an early warning sign for the likelihood of developing Barret’s oesophagus, and potentially oesophageal cancer.

“We propose developing a simple tick box questionnaire, identifying risks such as a large waist circumference, severe stomach pain and duration of heartburn, which could be filled out by a GP or by a patient using a mobile phone app.

“The results would identify a high risk group of people at an early stage, who could then go on to have clinical screening to diagnose and treat oesophageal cancer at a much earlier stage and significantly improve survival rates.” – Lead author, Professor Laurence Lovat (UCL Surgery & Interventional Science).

DISCOVER MORE:

Guts UK is a proud founding charity member of the Less Survivable Cancers Taskforce. This task force is a group of charities, aiming to double survival rates for the six least survivable cancers by 2029. Four of these six cancers are digestive; stomach, pancreatic, oesophageal and liver.

Discover how you can get involved here, email us at info@gutscharity.org.uk or call 01484 483123 to learn more. We love to hear from you.

 

MORE INFORMATION:

Read more posts...

The Gut Quiz

Team Guts UK have created a quiz to help you with any fundraising you’re taking on! The quiz is jam-packed with interesting facts, from the microbes that live in our gut to saliva – we’ve...

25th February 2020

What questions would you like to see answered by research?

The National Institute for Health Research (NIHR) need your help to identify and update the priorities in gastrointestinal care that are ready for research, to complement wider priority setting activities in this area. The NIHR are seeking research...

10th February 2020

UK ranks poorly for deadliest cancer survival

Guts UK is a founding member of the Less Survivable Taskforce and we’re calling for government support on World Cancer Day. This World Cancer Day, the Less Survivable Cancers Taskforce (LSCT) is calling on UK...

4th February 2020

World Cancer Day 2020

On 4th February, charities, individuals and organisations across the globe come together for World Cancer Day  – a day that unites people, communities and entire countries to take action. An important part of our work at...

4th February 2020

Oesophageal Cancer Awareness Month & Guts UK’s Research

February is Oesophageal Cancer Awareness Month so the Guts UK team will be busy raising awareness of risk factors and symptoms of oesophageal cancer, and spreading the word about the research we fund into oesophageal...

2nd February 2020